Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
Gorochov G, Ropers J, Launay O, Dorgham K, da Mata-Jardin O, Lebbah S, Durier C, Bauer R, Radenne A, Desaint C, Vieillard LV, Rekacewicz C, Lachatre M, Parfait B, Batteux F, Hupé P, Ninove L, Lefebvre M, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Botelho-Nevers E, Lelièvre JD, de Lamballerie X, Kieny MP, Tartour E, Paul S. Gorochov G, et al. Among authors: melica g. JAMA Netw Open. 2024 Apr 1;7(4):e248051. doi: 10.1001/jamanetworkopen.2024.8051. JAMA Netw Open. 2024. PMID: 38652471 Free PMC article.
Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.
Durier C, Ninove L, Lefebvre M, Radenne A, Desaint C, Ropers J, Bauer R, Lebbah S, Carette D, Lachatre M, Lecompte AS, Deplanque D, Botelho-Nevers E, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian J, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Priet S, Levier A, Molino D, Vieillard LV, Parfait B, Lelièvre JD, Tartour E, de Lamballerie X, Launay O; ANRS0002S CoviCompareP Group; AP-HP CoviCompareM Group; Biological resource centers; Laboratories; Trial coordination; Sponsor; Scientific Committee. Durier C, et al. Among authors: melica g. Sci Rep. 2022 Nov 27;12(1):20373. doi: 10.1038/s41598-022-24409-w. Sci Rep. 2022. PMID: 36437298 Free PMC article.
Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
Durier C, Ninove L, van der Werf S, Lefebvre M, Desaint C, Bauer R, Attia M, Lecompte AS, Lachatre M, Maakaroun-Vermesse Z, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Corbin V, Ansart S, Melica G, Resch M, Netzer E, Kherabi Y, Tardieu R, Lelièvre JD, Tartour E, Meyer L, de Lamballerie X, Launay O; ANRS002S CoviCompareP group. Durier C, et al. Among authors: melica g. Infect Dis Now. 2024 Mar 16;54(5):104886. doi: 10.1016/j.idnow.2024.104886. Online ahead of print. Infect Dis Now. 2024. PMID: 38494117 Free article.
Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.
Attias P, Azzaoui I, El Karoui K, de La Selle A, Sokal A, Chappert P, Grimbert P, Fernandez I, Bouvier M, Samson C, Dahmane D, Rieu P, Nizard P, Fourati S, Sakhi H, Mahévas M; Mondor NephroCov Study Group. Attias P, et al. Clin J Am Soc Nephrol. 2022 Jul;17(7):1008-1016. doi: 10.2215/CJN.00830122. Epub 2022 Jun 28. Clin J Am Soc Nephrol. 2022. PMID: 35764393 Free PMC article.
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies.
Gressens SB, Fourati S, Le Bouter A, Le Bras F, Dupuis J, Hammoud M, El Gnaoui T, Gounot R, Roulin L, Belhadj K, Haioun C, Gallien S, Melica G, Lemonnier F. Gressens SB, et al. Among authors: melica g. Clin Microbiol Infect. 2022 Jun;28(6):885.e7-885.e11. doi: 10.1016/j.cmi.2022.02.029. Epub 2022 Mar 5. Clin Microbiol Infect. 2022. PMID: 35259530 Free PMC article.
104 results